---
title: Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC by CT Images and Pathological Factors
nct_id: NCT06737367
overall_status: COMPLETED
sponsor: Jinling Hospital, China
study_type: OBSERVATIONAL
primary_condition: Lung Cancer - Non Small Cell
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06737367.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06737367"
ct_last_update_post_date: 2024-12-19
last_seen_at: "2026-05-12T07:19:24.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC by CT Images and Pathological Factors

**Official Title:** Integrating Machine Learning for Prognostic Prediction in Stage I NSCLC: a Multicenter Analysis

**NCT ID:** [NCT06737367](https://clinicaltrials.gov/study/NCT06737367)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 800
- **Lead Sponsor:** Jinling Hospital, China
- **Conditions:** Lung Cancer - Non Small Cell
- **Start Date:** 2023-09-01
- **Completion Date:** 2024-11-11
- **CT.gov Last Update:** 2024-12-19

## Brief Summary

The investigators retrospectively collected the participants with stage I non-small cell lung cancer (NSCLC) patients resected between January 2010 to December 2020 for training and internal validation. The Clinical data, preoperative clinical information, laboratory results and CT images were collected. The investigators also collected the disease-free survival time. On the Deepwise multi-modal research platform, the images were semi-automatically segmented and expanded outward by 3mm to obtain the peritumor tissue. PyRadiomics was used to extract the radiomic features. LASSOcox and rsf were used to select the features. we developed a machine learning-based integrative prognostic model that utilizes radiomic and pathological variables as input using LOOCV framework. And it was further tested on the internal and external cohorts. Discrimination was assessed by using the C-index and area under the receiver operating characteristic curve (AUC), IBS, DCA.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

patients with stage I NSCLC (ninth AJCC edition) who underwent curative R0 resections between January 2010 and December 2020 -

Exclusion Criteria:

1. absence of enhanced CT
2. history of lung cancer or synchronous lung cancers
3. follow-up records ≤3 Months
4. carcinoma in situ (CIS) or minimally invasive NSCLC
5. death within 30 days of surgery
6. no pathological slides or reports
```

## Arms

- **training set**
- **external test set**

## Interventions

- **CT radiomic analysis** (OTHER) — Radiomic features of tumor and peritumor tissue

## Primary Outcomes

- **DFS（Disease-free survival）** _(time frame: Record from the date of surgery to the date of recurrence or death from any cause, whichever comes first, and assess up to a maximum of 5 years.)_ — DFS was defined as the duration from the date of primary surgery to the first occurrence of recurrence or death from any cause.

## Locations (1)

- Jinling Hospital, China, Nanjing, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.jinling hospital, china|nanjing||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06737367.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06737367*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*